Business
Acrivon Therapeutics Presents Data Demonstrating Capabilities of its AP3 Platform and ACR-368 OncoSignature Assay for Patient Responder Identification at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Data presented on the application of Acrivon Predictive Precision Proteomics (AP3) for the successful development and extensive evaluation of the
About this update from Acrivon Therapeutics, Inc.
[{"type":"text","content":"Data presented on the application of Acrivon Predictive Precision Proteomics (AP3) for the successful development and extensive evaluation of the ACR-368-tailored, proteomics-based OncoSignature assay for the prediction of patients, as well as tumor types, most likely to respond to the CHK1/2 inhibitor ACR-368 ACR-368 OncoSignature assay being utilized in the registrational-intent Phase 2 trial of ACR-368 for patients with ovarian, endometrial, or bladder cancer WATERTOWN, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, announced data highlighting its AP3 approach to identify and evaluate biomarkers for its OncoSignature assay designed specifically to predict sensitivity to ACR-368, the company’s selective small molecule inhibitor targeting CHK1 and CHK2, currently in registrational-intent Phase 2 clinical trials. The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston this past week. “Our AP3 platform is designed to directly measure the activity state of the drug-regulated, disease-driving proteins and drug-induced compensatory resistance mechanisms to enable an exact match with drug mechanism-of-action, independent of genetic alterations,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics. “We leverage this distinctive capability to create drug-tailored OncoSignature assays as a companion diagnostic aiming to identify and treat patients most likely to benefit from treatment. We are excited to have presented some key data supporting these pioneering technologies and their application in the clinical development of ACR-368 at this year’s AACR-NCI-EORTC conference.” Acrivon Posters Presented at This Year’s AACR-NCI-EORTC Conference The poster (#C002) titled “Identification of Biomarkers Predictive of Sensitivity to the CHK1/2 Inhibitor ACR-368 Using High-Resolution Phosphoproteomics and Development of an ACR-368-Tailored Patient Responder Identificati...